Suppr超能文献

从风险评估到管理:肾移植受者术前及术后的心血管并发症:一篇叙述性综述

From Risk Assessment to Management: Cardiovascular Complications in Pre- and Post-Kidney Transplant Recipients: A Narrative Review.

作者信息

Beaudrey Thomas, Bedo Dimitri, Weschler Célia, Caillard Sophie, Florens Nans

机构信息

Nephrology Department, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France.

Inserm UMR_S 1109 Immuno-Rhumatology Laboratory, Translational Medicine Federation of Strasbourg (FMTS), FHU Target, Faculté de Médecine, Université de Strasbourg, 67000 Strasbourg, France.

出版信息

Diagnostics (Basel). 2025 Mar 21;15(7):802. doi: 10.3390/diagnostics15070802.

Abstract

Kidney transplantation remains the best treatment for chronic kidney failure, offering better outcomes and quality of life compared with dialysis. Cardiovascular disease (CVD) is a major cause of morbidity and mortality in kidney transplant recipients and is associated with decreased patient survival and worse graft outcomes. Post-transplant CVD results from a complex interaction between traditional cardiovascular risk factors, such as hypertension and diabetes, and risk factors specific to kidney transplant recipients including chronic kidney disease, immunosuppressive drugs, or vascular access. An accurate assessment of cardiovascular risk is now needed to optimize the management of cardiovascular comorbidities through the detection of risk factors and the screening of hidden pretransplant coronary artery disease. Promising new strategies are emerging, such as GLP-1 receptor agonists and SGLT2 inhibitors, with a high potential to mitigate cardiovascular complications, although further research is needed to determine their role in kidney transplant recipients. Despite this progress, a significant gap remains in understanding the optimal management of post-transplant CVD, especially coronary artery disease, stroke, and peripheral artery disease. Addressing these challenges is essential to improve the short- and long-term outcomes in kidney transplant recipients. This narrative review aims to provide a comprehensive overview of cardiovascular risk assessment and post-transplant CVD management.

摘要

肾移植仍然是慢性肾衰竭的最佳治疗方法,与透析相比,能带来更好的治疗效果和生活质量。心血管疾病(CVD)是肾移植受者发病和死亡的主要原因,与患者生存率降低和移植物预后较差相关。移植后心血管疾病是由传统心血管危险因素(如高血压和糖尿病)与肾移植受者特有的危险因素(包括慢性肾病、免疫抑制药物或血管通路)之间复杂的相互作用引起的。现在需要对心血管风险进行准确评估,以便通过检测危险因素和筛查隐匿的移植前冠状动脉疾病来优化心血管合并症的管理。有前景的新策略正在出现,如胰高血糖素样肽-1受体激动剂和钠-葡萄糖协同转运蛋白2抑制剂,虽然需要进一步研究以确定它们在肾移植受者中的作用,但它们具有减轻心血管并发症的巨大潜力。尽管取得了这一进展,但在理解移植后心血管疾病(尤其是冠状动脉疾病、中风和外周动脉疾病)的最佳管理方面仍存在显著差距。应对这些挑战对于改善肾移植受者的短期和长期预后至关重要。本叙述性综述旨在全面概述心血管风险评估和移植后心血管疾病的管理。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7005/11988545/d3d97cf4acfd/diagnostics-15-00802-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验